The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Abstract
After DNA damage, many cells appear to enter a sustained arrest in the G 2 phase of the cell cycle. It is shown here that this arrest could be sustained only when p53 was present in the cell and capable of transcriptionally activating the cyclin-dependent kinase inhibitor p21. After disruption of either the p53 or the p21 gene, γ radiated cells progressed into mitosis and exhibited a G 2 DNA content only because of a failure of cytokinesis. Thus, p53 and p21 appear to be essential for maintaining the G 2 checkpoint in human cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p21 is required for p53-mediated G1/S146, 147, 148 and also for G2/M cell cycle arrest.149”
From Census and evaluation of p53 target genes (2017) · cites this paper as [149]
In the citing paper
“Indeed, after transiently arresting in G2, HCT-116 cells in which p21 was knocked out eventually underwent aberrant mitoses, leading to polyploidy or cell death.53,55”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [55]
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Self-citationp21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691
Universal control mechanism regulating onset of M-phase
Nurse, P. (1990) · Nature · doi:10.1038/344503a0 · Cited by 2,798
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,539
p53: puzzle and paradigm.Preprint
Ko, L. J., & Prives, C. L. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,346
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Mutations of mitotic checkpoint genes in human cancers
Cahill, D. P., Lengauer, C., Yu, J., Riggins, G. J., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/32688 · Cited by 1,490
Self-citationPeng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251
Self-citation
Research works printed but not linked: 13
- Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W., Cancer Res. 51, 6304 (1991);
- Waldman T., Kinzler K. W., Vogelstein B., Cancer Res. 55, 5187 (1995).
- Powell S. N., et al., Cancer Res. 55, 1643 (1995);
- Fan S., et al., Cancer Res. 55, 1649 (1995);
- Russell K. J., et al., ibid. 55, 1639 (1995).
- Khan S. H., Wahl G. M., Cancer Res. 58, 396 (1998);
- Michieli P., et al., Cancer Res. 54, 3391 (1994);
- Paules R. S., et al., Cancer Res 55, 1763 (1995);
- Stewart N., Hicks G. G., Paraskeva F., Mowat M., Oncogene 10, 109 (1995).
- Li Y., Jenkins C. W., Nichols M. A., Xiong Y., Oncogene 9, 2261 (1994).
- Niculescu A. B., et al., Mol. Cell. Biol. 18, 629 (1998). · DOI
- El-Deiry W. S., et al., Cancer Res. 55, 2910 (1995);
- Kaufmann K., et al., Cell Growth. Diff. 8, 1105 (1997);
Cited by
Sorted by citations
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Metadata
- Authors
- Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- F. Bunz, S. Zhou, B. Vogelstein, The Howard Hughes Medical Institute and The Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA. C. Lengauer and K. W. Kinzler, The Johns Hopkins Oncology Center, Baltimore, MD 21231, USA. A. Dutriaux, J. P. Brown, J. Sedivy, Department of Molecular Biology, Cell Biology, and Biochemistry, Division of Biology and Medicine, Brown University, Providence, RI 02912, USA. T. Waldman, Program in Human Genetics and the Johns Hopkins Oncology...
- Corresponding author
- Vogelstein, B.
- Venue
- Science
- Published
- 1998-11-20
- Volume
- 282
- Issue
- 5393
- Pages
- 1497-1501
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2080125477
- Cited by
- 2,803
- References
- 50
- Citations by year
- 2026: 28 · 2025: 39 · 2024: 42 · 2023: 60 · 2022: 69 · 2021: 86 · 2020: 77 · 2019: 76 · 2018: 98 · 2017: 101 · 2016: 103 · 2015: 97 · 2014: 113 · 2013: 155 · 2012: 120
- FWCI
- 41.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 57345, CA43460, P50CA062924, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p53, p21, G2 checkpoint, DNA damage, cell cycle arrest, cyclin-dependent kinase inhibitors, transcriptional activation, gamma radiation, cytokinesis, mitosis, gene disruption
- MeSH terms
- Cell Line, DNA, DNA Damage, Gamma Rays, Gene Expression Regulation, Humans, Mitosis, Mutation, Tumor Cells, Cultured, Nocodazole, Genes, p53, Tumor Suppressor Protein p53, G2 Phase, CDC2 Protein Kinase, Cyclins, Apoptosis, Cyclin B, Cyclin-Dependent Kinase Inhibitor p21, Cyclin B1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
